Back to Connor, Clark & Lunn Investment Management Ltd. Connor, Clark & Lunn Investment Management Ltd.

AMLX

Showing 9 of 13 quarters

Position history for Connor, Clark & Lunn Investment Management Ltd.Connor, Clark & Lunn Investment Management Ltd.'s holdings in Amylyx Pharmaceuticals, Inc.

Yes. Connor, Clark & Lunn Investment Management holds 680,496 shares of AMLX (Amylyx Pharmaceuticals), worth $19.8M, as of its Q3 2026 13F filing. It reduced the position by 40,506 shares (-5.6%) from Q2 2026. Connor, Clark & Lunn Investment Management has held AMLX since Q3 2023, across 13 quarterly 13F filings.

Current Value

$19.8M

Current Shares

680,496

Total Value Change

+$16.9M

Total Shares Change

-200,249

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q3
Latest
Decreased
680,496
-5.6%
$19.8M0.0%$29.10
0
2026-Q2
Decreased
721,002
-17.0%
$12.9M0.0%$17.96
0
2026-Q1
Decreased
868,325
-13.5%
$12.1M0.0%$13.90
0
2025-Q4
Decreased
1M
-9.3%
$12.1M0.0%$12.08
0
2025-Q3
Decreased
1.1M
-4.1%
$15M0.0%$13.59
0
2025-Q2
Decreased
1.2M
-3.8%
$7.4M0.0%$6.41
0
2025-Q1
Decreased
1.2M
-5.0%
$4.2M0.0%$3.54
0
2024-Q4
Increased
1.3M
+43.4%
$4.8M0.0%$3.78
36
2024-Q3
Increased
880,745
+41.6%
$2.9M0.0%$3.08
35

Other major holders of AMLX: FMR LLC, Viking Global Investors LP

Optional analytics helps us improve. How it’s used